Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine

Clinical Schizophrenia and Related Psychoses

Volumn 5, Issue 1, 2011, Pages 17-25

  Ball, M Patricia ^a   Warren, Kimberly R ^a   Feldman, Stephanie ^a   McMahon, Robert P ^a   Kelly, Deanna L ^a   Buchanan, Robert W ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotics; Obesity; Schizophrenia

Indexed keywords

ATOMOXETINE; CLOZAPINE; OLANZAPINE; PLACEBO;

ADULT; AGED; ARTICLE; BODY MASS; BRIEF PSYCHIATRIC RATING SCALE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONCENTRATION LOSS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; EATING HABIT; EXERCISE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; MALE; NERVOUSNESS; NEUROPSYCHOLOGICAL TEST; PHYSICAL ACTIVITY; PSYCHOLOGIC TEST; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOM; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ANTIPSYCHOTIC AGENTS; APPETITE DEPRESSANTS; ATTENTION; BENZODIAZEPINES; BODY MASS INDEX; BODY WEIGHT; BRIEF PSYCHIATRIC RATING SCALE; CLOZAPINE; COMBINED MODALITY THERAPY; DIET, REDUCING; DOUBLE-BLIND METHOD; EXERCISE; FEMALE; HUMANS; LIFE STYLE; MALE; MARYLAND; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OBESITY; PROPYLAMINES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 79953820744     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.5.1.3     Document Type: Article

References (53)

1. Brixner DI, Said Q, Corey-Lisle PK, Tuomari AV, L'italien GJ, Stockdale W, et al. Naturalistic impact of second-generation antipsychotics on weight gain. Ann Pharmacother 2006;40(4):626-632.
2. Ganguli R. Weight gain associated with antipsychotic drugs. J Clin Psychiatry 1999;60(21):20-24. (Pubitemid 29523629)
3. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000;157(6):975-981. (Pubitemid 30412350)
4. Baymiller SP, Ball P, McMahon RP, Buchanan RW. Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent β-adrenergic antagonist treatment. Schizophr Res 2003;59(1):49-57. (Pubitemid 35284493)
5. Buchanan RW, Ball MP, Weiner E, Kirkpatrick B, Gold JM, McMahon RP, et al. Olanzapine treatment of residual positive and negative symptoms. Am J Psychiatry 2005;62(1):124-129. (Pubitemid 40095681)
6. Hennekins CH, Hennekins AR, Hollar D, Casey DE. Schizophrenia and increased risk of cardiovascular disease. Am Heart J 2005;150 (6):1115-1121. (Pubitemid 41773510)
7. Aquila R, Emanuel M. Interventions for weight gain in adults treated with novel antipsychotics. Prim Care Companion J Clin Psychiatry 2000;2(1):20-23.
8. Ball P, Warren K, Buchanan R. Food choices and potential for weight loss in patients on second generation antipsychotics. Schizophr Bull 2007;33(2):481.
9. Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Schizophr Bull 2007;33(3):654-656. (Pubitemid 47343724)
10. Greenberg I, Chan S, Blackburn GL. Nonpharmacologic and pharmacologic management of weight gain. J Clin Psychiatry 1999;60(21):31-36. (Pubitemid 29523631)
11. Hoffmann VP, Ahl J, Meyers A, Schuh L, Shults KS, Collins DM, et al. Wellness intervention for patients with serious and persistent mental illness. J Clin Psychiatry 2005;66(12):1576-1579. (Pubitemid 43068698)
12. Kwon JS, Choi JS, Bahk WM, Yoon Kim C, Hyung Kim C, Chul Shin Y, et al. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: a 12-week randomized controlled clinical trial. J Clin Psychiatry 2006;67(4):547-553. (Pubitemid 43764231)
13. Lee SJ, Choi EJ, Kwon JS. A naturalistic multicenter trial of a 12-week weight management program for overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2008;69(4):555-562. (Pubitemid 351792329)
14. Sharpe JK, Stedman TJ, Byrne NM, Wishart C, Hills AP. Energy expenditure and physical activity in clozapine use: implications for weight management. Aust N Z J Psychiatry 2006;40(9):810-814. (Pubitemid 44145226)
15. Vreeland B, Minsky S, Menza M, Rigassio Radler D, Roemheld-Hamm B, Stern R. A program for managing weight gain associated with atypical antipsychotics. Psychiatr Serv 2003;54(8):1155-1157. (Pubitemid 36951518)
16. Wu MK, Wang CK, Bai YM, Huang CY, Lee SD. Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program. Psychiatr Serv 2007;58(4):544-550.
17. Ball MP, Coons VB, Buchanan RW. A program for treating olanzapine-related weight gain. Psychiatr Serv 2001;52(7):967-969. (Pubitemid 32634719)
18. Baptista T, Martínez J, Lacruz A, Rangel N, Beaulieu S, Serrano A, et al. Met- formin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry 2006;51(3):192-196.
19. Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naïve first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry 2008;165(3):352-358.
20. Atmaca M, Kuloglu M, Tezcan E, Ustundag B, Kilic N. Nizatidine for the treatment of patients with quetiapine-induced weight gain. Hum Psychopharmacol 2004;19(1):37-40. (Pubitemid 38159274)
21. Cavazzoni P, Tanaka Y, Roychowdhury SM, Breier A, Allison DB. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 2003;13(2):81-85. (Pubitemid 36321748)
22. Poyurovsky M, Tal V, Maayan R, Gli-Ad I, Fuchs C, Weizman A. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. Eur Neuropsychopharmacol 2004;14(4):332-336. (Pubitemid 38649091)
23. Bustillo JR, Lauriello J, Parker K, Hammond R, Rowland L, Bogenschutz M, et al. Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Neuropsychopharmacology 2003;28(3):527-529.
24. Correa N, Opler LA, Kay SR, Birmaher B. Amantadine in the treatment of neuroendocrine side effects of neuroleptics. J Clin Psychopharmacol 1987;7(2):91-95. (Pubitemid 17053370)
25. Deberdt W, Winokur A, Cavazzoni PA, Trzaskoma QN, Carlson CD, Bymaster FP, et al. Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol 2005;15(1):13-21. (Pubitemid 39574395)
26. Graham KA, Gu H, Lieberman JA, Harp JB, Perkins DO. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry 2005;162(9):1744-1746. (Pubitemid 41318248)
27. Lévy E, Agbokou C, Ferreri F, Chouinard G, Margolese HC. Topiramate-induced weight loss in schizophrenia: a retrospective case series study. Can J Clin Pharmacol 2007;14(2):e234-239.
28. Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, et al. A double-blind, placebo-controlled trial of sibutramine for olanzapineassociated weight gain. Am J Psychiatry 2005;162(5):954-962. (Pubitemid 40676209)
29. Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998;155(5):693-695. (Pubitemid 28225414)
30. Poyurovsky M, Fuchs C, Pashinian A, Levi A, Faragian S, Maayan R, et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapinetreated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology (Berl) 2007;192(3):441-448. (Pubitemid 46701583)
31. Friedman JI, Carpenter D, Lu J, Fan J, Tang CY, White L, et al. A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. J Clin Psychopharmacol 2008;28(1):59-63.
32. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10(79):812.
33. Andreason NC. The Scale for the Assessment of Negative Symptoms (SANS). Iowa City (IA): University of Iowa; 1983.
34. Guy W. ECDEU assessment manual for psychopharmacology, revised (DHEW Publication No. ADM 76-338). Rockville (MD): US Department of Health and Human Services; 1976.
35. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19.
36. Wechsler D. Wechsler Adult Intelligence Scale. 3rd ed. San Antonio (TX): The Psychological Corporation; 1997.
37. Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 2004;68(2-3):283-297. (Pubitemid 38526150)
38. Matthews CG, Klove H. Instruction manual for the Adult Neuropsychology Test Battery. Madison (WI): University of Wisconsin Medical School; 1964.
39. Benton AL, Hamsher K. Multilingual Aphasia Examination. Iowa City (IA): AJA Associates, Inc.; 1989.
40. Woodcock RW, McGrew KS, Mather N. Woodcock-Johnson III Battery. Itasca (IL): Riverside Publishing; 2001.
41. Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test. 2nd ed. New York (NY): Psychological Corporation; 2000.
42. Benedict RHP. Brief Visuospatial Memory Test-Revised. Odessa (FL): Psychological Assessment Resources; 1997.
43. Gordon M, Mettelman BB. Technical guide to the Gordon Diagnostic System. New York (NY): De Witt; 1987.
44. Mallinckrodt CH, Kaiser CJ, Watkin JG, Molenberghs G, Carroll RJ. The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVA. Clin Trials 2004;1:477-489.
45. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, et al.; Atomoxetine ADHD Study Group. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001;108(5):E83.
46. Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics 1997;53(3):983-997. (Pubitemid 27391027)
47. McMahon RP, Arndt S, Conley RR. More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk. Stat Med 2005;24(1):11-21. (Pubitemid 40074061)
48. Conover WJ, Salsburg DS. Locally most powerful tests for detecting treatment effects when only a subset of patients can be expected to "respond" to treatment. Biometrics 1988;44(1):189-196.
49. Kelly DL, Buchanan RW, Boggs DL, McMahon RP, Dickinson D, Nelson M, et al. A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clin Psychiatry 2009;70(4):518-525.
50. Faulkner G, Cohn TA. Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications. Can J Psychiatry 2006;51(8):502-511. (Pubitemid 44166338)
51. Faulkner G, Soundy AA, Lloyd K. Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatr Scand 2003;108(5):324-332. (Pubitemid 37305124)
52. Dixon L. The 2009 schizophrenia PORT psychosocial treatment recommendations. Schizophr Bull 2009;35(1):129.
53. Archie SM, Goldberg JO, Akhtar-Danesh N, Landeen J, McColl L, McNiven J. Psychotic disorders, eating habits, and physical activity: who is ready for lifestyle changes? Psychiatr Serv 2007;58(2):233-239.